Neion Bio exited stealth and signed its first co-development and supply agreement with a major global pharmaceutical company, establishing near-term commercial momentum for its egg-based recombinant biologics platform. The company’s Raptor platform is engineered to produce therapeutic proteins using re-engineered egg-derived vesicles, aiming for scalable and consistent manufacturing. Neion said the partnership includes upfront and milestone payments plus long-term participation through profit sharing once products are commercialized. The company positioned the platform as a way to reduce the capital intensity and process constraints associated with traditional cell-culture manufacturing. By emphasizing egg vesicles as a reproducible production system—supported by recent advances in precision genome engineering and availability of avian primordial germ cells—Neion is betting that protein manufacturing can become faster to develop and easier to localize.